All Stories

AACR: Boehringer Ingelheim proves durability of 'unparalleled' HER2-mutant lung cancer candidate

The latest data drop for tyrosine kinase inhibitor zongertinib reflects an "unparalleled" risk/benefit profile, Boehringer’s global head of oncology, SVP Itziar Canamasas, Ph.D., said.

Apr 28, 2025 - 14:13
 0
AACR: Boehringer Ingelheim proves durability of 'unparalleled' HER2-mutant lung cancer candidate
The latest data drop for tyrosine kinase inhibitor zongertinib reflects an "unparalleled" risk/benefit profile, Boehringer’s global head of oncology, SVP Itziar Canamasas, Ph.D., said.
Read More

Tags:

Previous Article

Cvent Acquires Spatial Event Design Technology Provider Prismm

Next Article

STAT+: Pharmalittle: We’re reading about tariffs increasing U.S. drug costs, Tru...

Related Posts

M&A remains ‘top priority’ for Big Pharmas in the face of tariff threat

M&A remains ‘top priority’ for Big Pharmas in the face ...

Apr 25, 2025  0

Etiome emerges with $50M from Flagship Pioneering and goal of preempting disease

Etiome emerges with $50M from Flagship Pioneering and g...

Apr 24, 2025  0

Tempus AI in line for $200M from AstraZeneca, Pathos deal to develop cancer model

Tempus AI in line for $200M from AstraZeneca, Pathos de...

Apr 23, 2025  0